These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20061004)

  • 1. Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: a meta-analysis.
    Valachis A; Polyzos NP; Georgoulias V; Mavroudis D; Mauri D
    Gynecol Oncol; 2010 Apr; 117(1):139-45. PubMed ID: 20061004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials.
    Mauri D; Valachis A; Polyzos NP; Tsali L; Mavroudis D; Georgoulias V; Casazza G
    J Natl Compr Canc Netw; 2010 Mar; 8(3):279-86. PubMed ID: 20202461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K; Blinder VS; Elkin EB
    J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates in adjuvant setting for breast cancer: a review of the meta-analysis of bisphosphonates' effects on breast cancer recurrence presented in December 2013 at San Antonio Breast Conference.
    Costa L
    Curr Opin Support Palliat Care; 2014 Dec; 8(4):414-9. PubMed ID: 25319273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer.
    Strobl S; Wimmer K; Exner R; Devyatko Y; Bolliger M; Fitzal F; Gnant M
    Curr Treat Options Oncol; 2018 Mar; 19(4):18. PubMed ID: 29527635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
    Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis.
    Mauri D; Valachis A; Polyzos IP; Polyzos NP; Kamposioras K; Pesce LL
    Breast Cancer Res Treat; 2009 Aug; 116(3):433-9. PubMed ID: 19521766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonates: ready for use as adjuvant therapy of breast cancer?
    Theriault RL
    Curr Opin Obstet Gynecol; 2010 Feb; 22(1):61-6. PubMed ID: 19934757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of bisphosphonates in the adjuvant setting for breast cancer.
    Reeder JG; Brufsky AM
    Oncology (Williston Park); 2010 May; 24(6):462-7, 475. PubMed ID: 20568587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab versus zoledronic acid to prevent aromatase inhibitors-associated fractures in postmenopausal early breast cancer; a mixed treatment meta-analysis.
    Abdel-Rahman O
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):885-91. PubMed ID: 27210216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.
    Hadji P; Coleman RE; Wilson C; Powles TJ; Clézardin P; Aapro M; Costa L; Body JJ; Markopoulos C; Santini D; Diel I; Di Leo A; Cameron D; Dodwell D; Smith I; Gnant M; Gray R; Harbeck N; Thurlimann B; Untch M; Cortes J; Martin M; Albert US; Conte PF; Ejlertsen B; Bergh J; Kaufmann M; Holen I
    Ann Oncol; 2016 Mar; 27(3):379-90. PubMed ID: 26681681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates and breast cancer incidence and recurrence.
    Chlebowski RT; Col N
    Breast Dis; 2011; 33(2):93-101. PubMed ID: 22142660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant bisphosphonates: a new standard of care?
    Gnant M
    Curr Opin Oncol; 2012 Nov; 24(6):635-42. PubMed ID: 23042123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
    Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
    Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
    Gnant M; Pfeiler G; Dubsky PC; Hubalek M; Greil R; Jakesz R; Wette V; Balic M; Haslbauer F; Melbinger E; Bjelic-Radisic V; Artner-Matuschek S; Fitzal F; Marth C; Sevelda P; Mlineritsch B; Steger GG; Manfreda D; Exner R; Egle D; Bergh J; Kainberger F; Talbot S; Warner D; Fesl C; Singer CF;
    Lancet; 2015 Aug; 386(9992):433-43. PubMed ID: 26040499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should bisphosphonates be utilized in the adjuvant setting for breast cancer?
    Lipton A
    Breast Cancer Res Treat; 2010 Aug; 122(3):627-36. PubMed ID: 20490653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates in multiple myeloma.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2010 Mar; (3):CD003188. PubMed ID: 20238320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
    Hadji P; Bundred N
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S4-10. PubMed ID: 18068489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.